AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
arginine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1549 | 74-79-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An essential amino acid that is physiologically active in the L-form.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 70 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.32 L/kg | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -1.208 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.129 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 0.859 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 1.710 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 93.020 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 60.880 | % | High | 1 |
| herg | hERG pIC50 | 5.502 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 2.183 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 8.054 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 89.160 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHUK,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FGFR1,FLT3,GRK2,GSK3B,IGF1R,IKBKB,ITK,JAK1,JAK2,JAK3,MAP2K1,MAP2K6,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK7,MAPK9,MAPKAPK2,MTOR,NTRK1,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 | 62 | |||
| kinase-selectivity-class | AXL,CAMK2D,CDK9,DDR1,EIF2AK3,EPHB4,GRK2,MAP2K6,MAP3K14,MAP3K21,MAPK7,SIK2,STK33,TEK,TGFBR1 | 15 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.910 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 2.897 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 93.560 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.168 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 88.090 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 1.194 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 85.450 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 95.790 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 583.445 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 23, 2021 | PMDA | FUJIFILM TOYAMA CHEMICAL Co., Ltd. | |
| Feb. 28, 1973 | FDA | PHARMACIA AND UPJOHN | |
| July 25, 2019 | EMA | Advanced Accelerator Applications |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hyperammonaemia | 74.66 | 24.66 | 17 | 1080 | 6458 | 90620892 |
| Foetal growth restriction | 63.40 | 24.66 | 16 | 1081 | 9364 | 90617986 |
| Hyperammonaemic crisis | 57.72 | 24.66 | 7 | 1090 | 49 | 90627301 |
| Infantile apnoea | 41.98 | 24.66 | 8 | 1089 | 1279 | 90626071 |
| Selective eating disorder | 38.25 | 24.66 | 8 | 1089 | 2045 | 90625305 |
| Cerebral haemorrhage | 32.18 | 24.66 | 13 | 1084 | 34509 | 90592841 |
| Ammonia increased | 31.19 | 24.66 | 8 | 1089 | 4978 | 90622372 |
| Right ventricular failure | 27.89 | 24.66 | 10 | 1087 | 19195 | 90608155 |
| Device related sepsis | 26.63 | 24.66 | 7 | 1090 | 4786 | 90622564 |
| Blood osmolarity decreased | 25.35 | 24.66 | 5 | 1092 | 954 | 90626396 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Haematuria | 80.06 | 24.77 | 37 | 1186 | 57762 | 42562350 |
| Hyperammonaemic crisis | 76.23 | 24.77 | 10 | 1213 | 53 | 42620059 |
| Blindness cortical | 55.64 | 24.77 | 10 | 1213 | 484 | 42619628 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hyperammonaemic crisis | 109.11 | 21.12 | 14 | 1919 | 108 | 110587258 |
| Haematuria | 78.16 | 21.12 | 35 | 1898 | 82970 | 110504396 |
| Hyperammonaemia | 68.80 | 21.12 | 20 | 1913 | 13712 | 110573654 |
| Blindness cortical | 52.27 | 21.12 | 10 | 1923 | 1125 | 110586241 |
| Ammonia increased | 41.24 | 21.12 | 12 | 1921 | 8238 | 110579128 |
| Blood osmolarity decreased | 26.72 | 21.12 | 6 | 1927 | 1472 | 110585894 |
| Status epilepticus | 25.54 | 21.12 | 12 | 1921 | 31559 | 110555807 |
| Drug ineffective | 22.91 | 21.12 | 68 | 1865 | 1520472 | 109066894 |
| Right ventricular failure | 21.41 | 21.12 | 10 | 1923 | 25944 | 110561422 |
| Ureaplasma infection | 21.14 | 21.12 | 5 | 1928 | 1541 | 110585825 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | B05XB01 | BLOOD AND BLOOD FORMING ORGANS BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS I.V. SOLUTION ADDITIVES Amino acids |
| ATC | V03AF11 | VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Detoxifying agents for antineoplastic treatment |
| CHEBI has role | CHEBI:27027 | micronutrient |
| CHEBI has role | CHEBI:50733 | nutraceutical |
| CHEBI has role | CHEBI:59163 | biomarker |
| CHEBI has role | CHEBI:75771 | mouse metabolite |
| CHEBI has role | CHEBI:76971 | <em>Escherichia coli</em> metabolite |
| CHEBI has role | CHEBI:78675 | fundamental metabolite |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:38068 | antimalarial |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
Related Drugs by ATC class:
B05XB Amino acids 2 drugs
V03AF Detoxifying agents for antineoplastic treatment 10 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Renal radiation exposure from Lutetium (177Lu) oxodotreotide | indication | 218190002 | |
| Diagnostic Test for Growth Hormone Secretion | indication | ||
| Renal tubular acidosis | contraindication | 1776003 | DOID:14219 |
| Classical phenylketonuria | contraindication | 7573000 | |
| Poisoning by digitalis glycoside | contraindication | 12876009 | |
| Hyperkalemia | contraindication | 14140009 | |
| Constipation | contraindication | 14760008 | DOID:2089 |
| Sarcoidosis | contraindication | 31541009 | DOID:11335 |
| Dehydration | contraindication | 34095006 | |
| End stage renal disease | contraindication | 46177005 | DOID:784 |
| Humoral hypercalcemia of malignancy | contraindication | 47709007 | |
| Heart disease | contraindication | 56265001 | DOID:114 |
| Metabolic acidosis | contraindication | 59455009 | |
| Hypercalcemia | contraindication | 66931009 | DOID:12678 |
| Hyperparathyroidism | contraindication | 66999008 | DOID:13543 |
| Ventricular fibrillation | contraindication | 71908006 | |
| Hypercalciuria | contraindication | 71938000 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Kidney stone | contraindication | 95570007 | |
| Hb SS disease | contraindication | 127040003 | DOID:10923 |
| Osteolysis | contraindication | 203522001 | |
| Myocardial infarction in recovery phase | contraindication | 418044006 | |
| Allergic Reactions | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 1.97 | acidic |
| pKa2 | 11.72 | Basic |
| pKa3 | 8.95 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Nitric oxide synthase, inducible | Enzyme | Kd | 5.15 | CHEMBL | |||||
| G-protein coupled receptor family C group 6 member A | GPCR | AGONIST | EC50 | 4.40 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| 4018668 | VUID |
| N0000146979 | NUI |
| D02982 | KEGG_DRUG |
| 1119-34-2 | SECONDARY_CAS_RN |
| 4018668 | VANDF |
| 4019067 | VANDF |
| C0003765 | UMLSCUI |
| CHEBI:29016 | CHEBI |
| ARG | PDB_CHEM_ID |
| CHEMBL1485 | ChEMBL_ID |
| CHEMBL1200381 | ChEMBL_ID |
| D001120 | MESH_DESCRIPTOR_UI |
| DB00125 | DRUGBANK_ID |
| 1711 | INN_ID |
| 94ZLA3W45F | UNII |
| 6322 | PUBCHEM_CID |
| DB17289 | DRUGBANK_ID |
| 1091 | RXNORM |
| 14778 | MMSL |
| 206 | MMSL |
| 399898 | MMSL |
| 40033 | MMSL |
| 4219 | MMSL |
| 7609 | MMSL |
| 7610 | MMSL |
| d00578 | MMSL |
| 000926 | NDDF |
| 005095 | NDDF |
| 52625008 | SNOMEDCT_US |
| 63676001 | SNOMEDCT_US |
| 721 | IUPHAR_LIGAND_ID |
| 94ZLA3W45F | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| R-Gene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0436 | INJECTION, SOLUTION | 10 g | INTRAVENOUS | NDA | 17 sections |
| TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-1933 | SOLUTION | 1.20 g | INTRAVENOUS | NDA | 23 sections |
| Plenamine | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0264-4500 | SOLUTION | 1.47 g | INTRAVENOUS | ANDA | 20 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0180 | INJECTION | 920 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0184 | INJECTION | 920 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0188 | INJECTION | 920 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0194 | INJECTION | 920 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0198 | INJECTION | 690 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0338-0202 | INJECTION | 920 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0338-0206 | INJECTION | 920 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0338-0210 | INJECTION | 920 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0338-0214 | INJECTION | 920 mg | INTRAVENOUS | NDA | 20 sections |
| ProSol | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0338-0499 | INJECTION, SOLUTION | 1.96 g | INTRAVENOUS | NDA | 21 sections |
| Clinisol | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0338-0502 | INJECTION, SOLUTION | 1.47 g | INTRAVENOUS | ANDA | 18 sections |
| Travasol | HUMAN PRESCRIPTION DRUG LABEL | 15 | 0338-0644 | INJECTION | 1.15 g | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1089 | INJECTION | 489 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1091 | INJECTION | 489 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1099 | INJECTION | 575 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1101 | INJECTION | 575 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1113 | INJECTION | 489 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1115 | INJECTION | 489 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1123 | INJECTION | 575 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1125 | INJECTION | 575 mg | INTRAVENOUS | NDA | 20 sections |
| Premasol - sulfite-free (Amino Acid) | HUMAN PRESCRIPTION DRUG LABEL | 19 | 0338-1130 | INJECTION, SOLUTION | 1.20 g | INTRAVENOUS | ANDA | 15 sections |
| Premasol - sulfite-free (Amino Acid) | HUMAN PRESCRIPTION DRUG LABEL | 19 | 0338-1131 | INJECTION, SOLUTION | 0.73 g | INTRAVENOUS | ANDA | 15 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1133 | INJECTION | 489 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1134 | INJECTION | 489 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1137 | INJECTION | 575 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1138 | INJECTION | 575 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1142 | INJECTION | 316 mg | INTRAVENOUS | NDA | 20 sections |